Equities

InDex Pharmaceuticals Holding AB

InDex Pharmaceuticals Holding AB

Actions
  • Price (SEK)0.404
  • Today's Change-0.004 / -0.98%
  • Shares traded1.98m
  • 1 Year change+3.86%
  • Beta-0.0207
Data delayed at least 15 minutes, as of May 08 2024 12:30 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

InDex Pharmaceuticals Holding AB is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company is focused in pharmaceuticals development. The Company's drug candidate is cobitolimod that helps in ulcerative colitis treatment. In addition, the Company develops a platform of patent protected substances, DNA based ImmunoModulatory Sequences (DIMS), that helps in the treatment of various immunological diseases. The Company also offers diagnostic kit DiBiCol, which is a PCR-based method that monitors seven biomarkers specific for ulcerative colitis or Crohn’s disease from a single colonic biopsy. InDex Pharmaceuticals Holding AB operates as a parent for InDex Pharmaceuticals AB and InDex Diagnostics AB. Among the Company's shareholders are SEB Venture Capital, Industrifonden and NeoMed Management.

  • Revenue in SEK (TTM)108.34m
  • Net income in SEK-56.48m
  • Incorporated2016
  • Employees7.00
  • Location
    InDex Pharmaceuticals Holding ABBerzelius Vag 13SOLNA 171 65SwedenSWE
  • Phone+46 812203850
  • Fax+46 850884739
  • Websitehttps://www.indexpharma.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Kancera AB0.00-64.89m169.90m3.00---------0.786-0.7860.00--------0.00---54.82---66.21-------7,249.06-------------23.64------
PMD Device Solutions AB28.62m-36.18m178.25m1.00------6.23-16.69-16.696.34-4.790.9465--57.42---119.63------58.18---126.39--0.0505-3.00----------------
Active Biotech AB publ0.00-45.80m191.00m11.00--6.23-----0.172-0.1720.000.08480.00-------96.37-57.97-126.15-97.83-------1,454.61----0.1291------21.54------
Saniona AB16.84m-95.81m204.01m23.00------12.11-1.28-1.280.226-0.28950.1546--4.71732,173.90-87.96-59.16-108.11-70.15-213.08-970.05-568.94-1,483.55---3.181.44--10.19-21.0554.71---34.94--
SenzaGen AB49.87m-22.10m210.92m34.00--3.12--4.23-0.9136-0.91362.062.800.45943.044.031,466,765.00-20.35-25.84-27.59-29.8570.0568.62-44.31-132.291.22--0.0242--19.3990.3211.30---21.10--
Corline Biomedical AB25.03m-1.81m215.98m13.00--2.31--8.63-0.0841-0.08411.164.340.248--10.921,925,385.00-1.79-5.71-1.92-6.24113.38128.60-7.22-38.46---89.400.00--6.2874.14-177.67--62.51--
Exact Therapeutics AS0.00-48.09m217.05m8.00--4.84-----1.51-1.510.001.410.00-------67.21-40.21-86.14-45.67-----------16,578.570.0258-------20.52------
InDex Pharmaceuticals Holding AB108.34m-56.48m217.34m7.00--0.921--2.01-0.1037-0.10370.20280.4430.3559----15,477,000.00-18.55-37.64-21.24-41.14-46.98-450.51-52.13-454.62----0.0086----277.025.05------
Thor Medical ASA0.00-5.53m237.48m1.00--0.8777-----0.0318-0.1520.001.160.00----0.00-2.52-79.17-2.84-113.94------------0.00--------------
Abliva AB137.00k-95.51m244.14m6.00--2.71--1,782.04-0.0904-0.09040.00010.0670.001--0.0034---70.40-74.59-80.95-86.98-14,491.24---69,714.60-65,958.89----0.00--341.9493.89-12.02---19.74--
Aqua Bio Technology ASA13.44m-1.50m245.38m2.00--11.46284.9118.25-0.1599-0.15990.49380.36730.30790.65489.01---3.42-80.72-6.75-125.2966.695.57-11.12-965.980.10440.6110.7538--349.8842.041.97------
Lipum AB (publ)0.00-37.18m245.91m----13.97-----4.05-4.050.000.47260.00-------159.35-127.85-206.31-184.50-------293,228.70----0.2781------2.38------
Ultimovacs ASA0.00-188.29m249.56m27.00--0.8977-----5.50-5.500.008.120.00----0.00-44.08-28.80-50.02-31.12------------0.0131-------12.78---45.35--
Lumito AB (publ)0.00-25.80m249.79m15.00--2.42-----0.125-0.1250.000.49970.00----0.00-19.98-20.77-22.14-22.38--------1.42--0.0884------4.56------
Arctic Bioscience AS33.58m-45.29m262.52m20.00--1.02--7.82-1.79-1.791.3310.190.10750.70252.931,687,501.00-14.50---16.61--28.96---134.86--2.53--0.0079---1.52---33.77------
Data as of May 08 2024. Currency figures normalised to InDex Pharmaceuticals Holding AB's reporting currency: Swedish Krona SEK

Institutional shareholders

9.82%Per cent of shares held by top holders
HolderShares% Held
Fj�rde AP-fondenas of 31 Dec 202352.31m9.82%
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.